



Telix Pharmaceuticals Limited

ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

Non-Executive Director Leave of Absence

Melbourne (Australia) – 29 March 2023. Telix Pharmaceuticals Limited ACN 616 620 369 (ASX: TLX, 'Telix' or 'Company') today advises that the Board of Directors ('Board') has granted Dr Andreas Kluge, on his request, a leave of absence, for a period of approximately six months, from his current role as a Non-Executive Director of Telix, to enable him to deal with personal issues.

The Telix Board anticipates that Dr Kluge will return from his leave of absence on or around 29 September 2023. We wish to extend our support to Dr Kluge at this time, and look forward to his return in September.

Dr Kluge is the Founder of ABX GmbH (www.abx.de), one of the leading manufacturers of radiopharmaceutical precursors globally. He is the Founder, General Manager and Medical Director for Therapiea Verwaltungs-GmbH, an early-stage development company in the field of neuro-oncology which was acquired by Telix. Dr Kluge has extensive experience in molecular imaging and the clinical development of novel radionuclide-based products and devices.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals-limited).

Telix's lead product, Illuccix, has been approved by the FDA,¹ and by the Australian Therapeutic Goods Administration (TGA),² and by Health Canada.³

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Chairman, Kevin McCann.

¹ ASX disclosure 20 December 2021.

² ASX disclosure 2 November 2021.

³ ASX disclosure 14 October 2022.